Commentary
Video
Dr. Tyson shares interim findings from the BOND-003 trial in NMIBC
Author(s):
Mark D. Tyson, II, MD, MPH, shares interim findings from the BOND-003 trial, evaluating cretostimogene grenadenorepvec in patients with high risk, papillary only, BCG-unresponsive non–muscle-invasive bladder cancer.
In this video, Mark D. Tyson, II, MD, MPH, shares the background and key findings from the study, “BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer,” which was presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Tyson is a urologic oncologist at Mayo Clinic in Phoenix, Arizona.
Related Videos
Related Content
